Effect of ellagic acid on thiol levels in different brain tissue in an animal model of Parkinson's disease

Document Type: Original article

Authors

1 Department of Biology, Faculty of Sciences, Izeh Branch, Islamic Azad University, Izeh, Iran

2 Department of Biology, Faculty of Sciences, Damghan Branch, Islamic Azad University, Damghan, Iran

Abstract

Background & Aim: Parkinson's disease (PD) can be created with loss of dopaminergic substantial nigra neurons which is widely associated with oxidative stress and reduced glutathione (GSH), as the most important and abundant thiol in tissues and one of the antioxidant defense, is one of the earliest biochemical events related to Parkinson's and consumption of antioxidants has a protective effect.  In the present study, effect of ellagic acid on the rate of thiol groups has been studied within the hippocampus, striatum, cortex and cerebellum tissues in Parkinson's disease. Experimental:  In this study were used 40 adult male rats that were divided randomly into eight groups: control, Parkinson's, and three Parkinson groups that once daily for 14 days received the gavage from doses 10, 25, and 50 mg/kg of ellagic acid. Parkinson's disease was induced with injection of 8 µg of 6_ hydroxy dopamine (6-OHDA) nerve toxin in 2 ml of saline containing 1% ascorbic acid in the middle-anterior bundle (MFB) of the left cerebral hemisphere of rats. After 14 days all rat brain were collected for the isolation and measurement of tissue thiol. Results & Discussion: In the PD group, in the all tissues observed a significant decrease in the thiol levels than the control group and administered ellagic acid in particular, 25 and 50 mg/kg was able to induce the effect of increase in the all tissues. This increase was significant in all tissues except cerebellum than PD group. Recommended applications/industries:  Ellagic acid with having the ability to increase thiol can be used for treating and preventing progression of Parkinson's disease that created by oxidative stress.

Keywords


Article Title [Persian]

اثر الاژیک اسید بر میزان تیول در بافت‌های مختلف مغزی در مدل حیوانی بیماری پارکینسون

Authors [Persian]

  • مریم رفیعی راد 1
  • زینب عیدی پور 2
1 گروه زیست شناسی، دانشکده علوم پایه، واحد ایذه، دانشگاه آزاد اسلامی، ایذه، ایران
2 گروه زیست شناسی، دانشکده علوم پایه، واحد دامغان، دانشگاه آزاد اسلامی،دامغان، ایران
Abstract [Persian]

مقدمه و هدف: بیماری پارکینسون(PD) با از بین رفتن نورون­های دوپامینرژیک جسم سیاه ایجاد می­گردد که به­طور گسترده­ای با استرس اکسیداتیو در ارتباط است و کاهش گلوتاتیون (GSH)، به عنوان فراوان­ترین و مهم­ترین تیول بافتی و یکی از عوامل دفاع آنتی­اکسیدانی از اولین وقایع بیوشیمیایی مرتبط با پارکینسون می­باشد و مصرف آنتی­اکسیدان­ها اثر حفاظتی دارد. در مطالعه حاضر اثر الاژیک اسید بر میزان گروه­های تیول در بافت­های هیپوکامپ، استریاتوم، قشر­مغز و مخچه در بیماری پارکینسون مورد بررسی قرار گرفته­­است. روش تحقیق: در این مطالعه از 40 سر موش صحرایی نر بالغ استفاده­گردید که به­طور تصادفی به گروه­های 8­تایی کنترل، پارکینسونی، و سه گروه پارکینسونی که روزانه یک­بار  به مدت 14 روز به ترتیب دوزهای  mg/kg10 ،25و 50 الاژیک اسید را به روش گاواژ دریافت نمودند، تقسیم گردیدند. بیماری پارکینسون با تزریق 8­ میکروگرم سم عصبی 6_هیدروکسی دوپامین (6-OHDA) در 2­میکرولیتر سالین دارای 1%  اسید اسکوربیک درون دسته میانی_قدامی (MFB) نیم­کره چپ مغز موش­ها القاء شد و پس از 14 روز مغز تمامی موش­ها جهت جداسازی بافت­ها و سنجش تیول استخراج گردیدند. نتایج و بحث: در گروه پارکینسونی در تمامی بافت­ها کاهش معنی­داری در میزان تیول نسبت به گروه کنترل مشاهده گردید و تجویز الاژیک اسید به­­ویژه دوز 25 و 50 mg/kg توانست در تمامی بافت ­ها اثر افزایشی را القاء نماید که این افزایش در تمامی بافت­ها بجز مخچه معنی­دار بود. در نهایت الاژیک اسید با توان افزایش تیول قادر است با استرس اکسیداتیو ناشی از پارکینسون مقابله نماید. توصیه کاربردی/ صنعتی: با توجه به نتایج حاصل ازین تحقیق و خاصیت آنتی اکسیدانی الاژیک اسید می­توان از آن جهت بهبود و منع پیشروی بیماری پارکینسون بهره برد.

Keywords [Persian]

  •  تیول  الاژیک اسید  پارکینسون  موش صحرایی

Ascacio-Valdes, J., E. Burboa, A. F. Aguilera-Carbo, M. Aparicio, R. Perez-Schmidt, R. Rodriguez, C. N. Aguilar, and F. Aguilera. 2013. Antifungal ellagitannin isolated from Euphorbia antisyphilitica Zucc. Asian Pacific Journal of Tropical Biomedicine., 3: 41-46.

Balarajah, S., and A. E. Cavanna. 2013. The pathophysiology of impulse control disorders in Parkinson disease. Behavioural Neurology., 26: 237-244.

Damier, P., E. C. Hirsch, P. Zhang, Y. Agid, and F. Javoy-Agid. 1993. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience., 52: 1-6.

Dauer, W., and S. Przedborski. 2003. Parkinson's disease: mechanisms and models. Neuron., 39 (6): 889-909.

Deneke, S. M. 2000. Thiol-based antioxidants. Current Topics in Cellular Regulation., 36: 151-180.

Dias, V., E. Junn, and M. M. Mouradian. 2013. The role of oxidative stress in Parkinson's disease. Journal of Parkinson's Disease., 3: 461-491.

Drechsel, D. A., L. P. Liang, and M. Patel. 2007. 1-methyl-4-phenylpyridinium-induced alterations of glutathione status in immortalized rat dopaminergic neurons. Toxicology and Applied Pharmacology., 220: 341-348.

Esmaeilzadeh, E. , Gardaneh, M., and V. H.R. 2012. The concomitant effect of shikonin and glutathione peroxidase-1 on enhanced survival of dopaminergic neurons against parkinsonian toxicity. Journal of Cell & Tissue., 3: 153-194

Girish, C., V. Raj, J. Arya, and S. Balakrishnan. 2013. Involvement of the GABAergic system in the anxiolytic-like effect of the flavonoid ellagic acid in mice. European Journal of Pharmacology., 710: 49-58

Golembiowska, K., A. Dziubina, M. Kowalska, and K. Kaminska. 2008. Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L-DOPA in the rat striatum. Pharmacological Reports., 60: 319-330.

Gungor, N., M. Ozyurek, K. Guclu, S. D. Cekic, and R. Apak. 2011. Comparative evaluation of antioxidant capacities of thiol-based antioxidants measured by different in vitro methods. . Talanta 83: 1650-1658.

Haddad, J. J., and H. L. Harb. 2005. L-gamma-Glutamyl-L-cysteinyl-glycine (glutathione; GSH) and GSH-related enzymes in the regulation of pro- and anti-inflammatory cytokines: a signaling transcriptional scenario for redox(y) immunologic sensor(s)? Molecular immunology 42: 987-1014.

Han, D. H., M. J. Lee, and J. H. Kim. 2006. Antioxidant and apoptosis-inducing activities of ellagic acid. Anticancer research 26: 3601-3606.

Henchcliffe, C., and M. F. Beal. 2008. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature clinical practice Neurology 4: 600-609.

Krishna Veni, N., Meyyanathan. S.N., and S. B. 2012. Analysis of ellagic acid in fresh and processed fruit products by high performance thin layer chromatography. International Research Journal of Pharmacy 3: 201-204.

Liu, S., T. H. Zeng, M. Hofmann, E. Burcombe, J. Wei, R. Jiang, J. Kong, and Y. Chen. 2011. Antibacterial activity of graphite, graphite oxide, graphene oxide, and reduced graphene oxide: membrane and oxidative stress. . ACS Nano., 5: 6971-6980.

Lovell, M. A., C. Xie, and W. R. Markesbery. 2000. Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. Free Radical Biology & Medicine., 29: 714-720.

Mansouri, M. T., Y. Farbood, M. J. Sameri, A. Sarkaki, B. Naghizadeh, and M. Rafeirad. 2013. Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in rats. Food Chemistry., 138: 1028-1033.

Martin, H. L., and P. Teismann. 2009. Glutathione--a review on its role and significance in Parkinson's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology., 23: 3263-3272.

Moskaug, J. O., H. Carlsen, M. C. Myhrstad, and R. Blomhoff. 2005. Polyphenols and glutathione synthesis regulation. The American Journal of Clinical Nutrition., 81: 277S-283S.

Myhrstad, M. C., H. Carlsen, O. Nordstrom, R. Blomhoff, and J. O. Moskaug. 2002. Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter. Free Radical Biology & Medicine., 32: 386-393

Ozkaya, A., Yılmaz, Ö., Sahin,  Z., Yuce,  A., and C. S. 2010. The effects of ellagic acid on some biochemical parameters in the liver of rats against oxidative stress induced by Aluminum. Kafkas Univ Vet Fak Derg., 16: 263-268.

Rafieirad, M., Ghasemzadeh Dehkordi, M., and R. L. 2014a. The Effect of ellagic acid on memory and pain induced by brain ischemia in adult male Rats. Zanjan University of Medical Sciences Journal., 22: 33-42.

Rafieirad, M., and Ghasemzadeh Dehkordi,Kh. 2014. Effect of ellagic acid on oxidative stress duo to brain ischemia/hypoperfusion in male rat. Journal of Herbal Drugs., 5: 1-6.

Rafieirad, M., Zangeneh Nezhad, Z., and A. E. 2014b. Neuroprotective effects of oral ellagic acid on locomotor activity and anxiety-induced by ischemia/hypoperfusion in Rat. Advances in Environmental Biology., 8: 83-88.

Sarkaki, A., Norooz Zare, F., Farbood, Y., and P. A.A. 2013. Impaired movements in 6-OHDA induced Parkinson’s rat model improves by pomegranate seed hydroalcoholic extract. Health MED Journal.,  7: 348-358.

Seeram, N. P., L. S. Adams, S. M. Henning, Y. Niu, Y. Zhang, M. G. Nair, and D. Heber. 2005. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. The Journal of nutritional Biochemistry., 16: 360-367.

Uzar, E., H. Alp, M. U. Cevik, U. Firat, O. Evliyaoglu, A. Tufek, and Y. Altun. 2012. Ellagic acid attenuates oxidative stress on brain and sciatic nerve and improves histopathology of brain in streptozotocin-induced diabetic rats. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology., 33: 567-574.